Morosini Deborah 4
4 · Prelude Therapeutics Inc · Filed Nov 18, 2021
Insider Transaction Report
Form 4
Morosini Deborah
EVP, Chief of Clinical Affairs
Transactions
- Exercise/Conversion
Common Stock
2021-11-16$12.85/sh+28,751$369,450→ 29,195 total - Sale
Common Stock
2021-11-16$15.87/sh−28,351$449,962→ 844 total - Sale
Common Stock
2021-11-16$16.43/sh−400$6,570→ 444 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-16−28,751→ 196,045 totalExercise: $12.85Exp: 2030-09-01→ Common Stock (28,751 underlying)
Footnotes (4)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.41 to $16.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.41 to $16.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]The stock option vested as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.